Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma

Robin Wachowiak; Steffi Mayer; Jussuf Kaifi; Florian Gebauer; Jakob R Izbicki; Martin Lacher; Maximilian Bockhorn; Michael Tachezy

Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma

Standard

Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma. / Wachowiak, Robin; Mayer, Steffi; Kaifi, Jussuf; Gebauer, Florian; Izbicki, Jakob R; Lacher, Martin; Bockhorn, Maximilian; Tachezy, Michael.

In: ANTICANCER RES, Vol. 36, No. 8, 08.2016, p. 3991-5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wachowiak, R, Mayer, S, Kaifi, J, Gebauer, F, Izbicki, JR, Lacher, M, Bockhorn, M & Tachezy, M 2016, 'Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma', ANTICANCER RES, vol. 36, no. 8, pp. 3991-5.

APA

Wachowiak, R., Mayer, S., Kaifi, J., Gebauer, F., Izbicki, J. R., Lacher, M., Bockhorn, M., & Tachezy, M. (2016). Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma. ANTICANCER RES, 36(8), 3991-5.

Vancouver

Wachowiak R, Mayer S, Kaifi J, Gebauer F, Izbicki JR, Lacher M et al. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma. ANTICANCER RES. 2016 Aug;36(8):3991-5.

Bibtex

@article{660531984d304f09aa0bbc12fc333033,

title = "Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma",

abstract = "BACKGROUND/AIM: Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues.MATERIALS AND METHODS: ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed.RESULTS: Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001).CONCLUSION: Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.",

keywords = "Journal Article",

author = "Robin Wachowiak and Steffi Mayer and Jussuf Kaifi and Florian Gebauer and Izbicki, {Jakob R} and Martin Lacher and Maximilian Bockhorn and Michael Tachezy",

year = "2016",

month = aug,

language = "English",

volume = "36",

pages = "3991--5",

journal = "ANTICANCER RES",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "8",

}

RIS

TY - JOUR

T1 - Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma

AU - Wachowiak, Robin

AU - Mayer, Steffi

AU - Kaifi, Jussuf

AU - Gebauer, Florian

AU - Izbicki, Jakob R

AU - Lacher, Martin

AU - Bockhorn, Maximilian

AU - Tachezy, Michael

PY - 2016/8

Y1 - 2016/8

N2 - BACKGROUND/AIM: Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues.MATERIALS AND METHODS: ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed.RESULTS: Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001).CONCLUSION: Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.

AB - BACKGROUND/AIM: Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues.MATERIALS AND METHODS: ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed.RESULTS: Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001).CONCLUSION: Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.

KW - Journal Article

M3 - SCORING: Journal article

C2 - 27466504

VL - 36

SP - 3991

EP - 3995

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 8

ER -